Literature DB >> 10228934

Neuroendoscopic third ventriculostomy in the management of fourth ventricular outlet obstruction.

A Mohanty1, B Anandh, V R Kolluri, S S Praharaj.   

Abstract

Acquired fourth ventricular outlet obstruction, an uncommon entity, has been conventionally managed by ventriculoperitoneal shunt placements or excision of the obstructing membranes. The role of endoscopic third ventriculostomy is highlighted in the present communication. Three patients presenting with symptoms of raised intracranial pressure were diagnosed to have fourth ventricular outlet obstruction by neuroimaging studies and underwent endoscopic third ventriculostomy. All the patients had relief of their symptoms in the postoperative period. Neuroimaging studies performed at follow-up revealed decrease in ventricular size in all. Endoscopic third ventriculostomy is a useful alternative in the management of acquired fourth ventricular outlet obstruction.

Entities:  

Mesh:

Year:  1999        PMID: 10228934     DOI: 10.1055/s-2008-1053362

Source DB:  PubMed          Journal:  Minim Invasive Neurosurg        ISSN: 0946-7211


  3 in total

Review 1.  Endoscopic third ventriculostomy for obstructive hydrocephalus.

Authors:  Dieter Hellwig; Joachim Andreas Grotenhuis; Wuttipong Tirakotai; Thomas Riegel; Dirk Michael Schulte; Bernhard Ludwig Bauer; Helmut Bertalanffy
Journal:  Neurosurg Rev       Date:  2004-11-27       Impact factor: 3.042

2.  Idiopathic fourth ventricle outlet obstruction successfully treated by endoscopic third ventriculostomy: a case report.

Authors:  Yukitomo Ishi; Katsuyuki Asaoka; Hiroyuki Kobayashi; Hiroaki Motegi; Taku Sugiyama; Yuka Yokoyama; Sumire Echizenya; Koji Itamoto
Journal:  Springerplus       Date:  2015-09-30

Review 3.  Endoscopic Treatment Strategy for a Disproportionately Large Communicating Fourth Ventricle: Case Series and Literature Review.

Authors:  Teppei Kawabata; Kazuhito Takeuchi; Yuichi Nagata; Takayuki Ishikawa; Jungsu Choo; Toshihiko Wakabayashi
Journal:  Neurol Med Chir (Tokyo)       Date:  2020-06-12       Impact factor: 1.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.